AI-enabled CMC acceleration
Applying structured, data-driven workflows across cell line, process, and analytical development to reduce timelines and improve comparability outcomes.
Next-generation biologics development
Accelerating Access to Essential Biologics
GokyoBio is building a next-generation biologics platform and pipeline to expand global access to essential therapies, starting with high-patient-impact immunology biosimilars and extending into underserved high-need indications.
Gokyo Lake, Everest Khumbu Region
Platform
An agile, modular platform built around speed, quality, and execution excellence.
Built with deep expertise in CMC development, scale-up, and manufacturing strategy.
Strategic partnerships
Strategic in-house and global regional partnerships support broader access to life-saving therapies.
Scalable pipeline
A focused pipeline built on a scalable CMC platform designed for efficient expansion.
Approach
A disciplined operating model from asset selection through program advancement.
Select
Prioritize high-patient-impact biosimilar assets in immunology, while selectively targeting underserved high-need indications.
Accelerate
An integrated development framework designed to enable efficient comparability, scalable manufacturing, and accelerated timelines.
Scale
Advance programs through co-development and manufacturing partnerships that support global reach.
Pipeline
Our initial pipeline includes a focused set of biologic programs across immunology and other high-need indications.
Program
Therapeutic Area
Stage
GKY-101
Immunology
Target Evaluation
GKY-102
Immunology
Target Evaluation
GKY-103
Undisclosed
Target Selection
Contact
Get in touch.
GokyoBio is preparing for its next phase of company and platform development. For partnership, investor, career, or strategic inquiries, email us directly.